Research Paper Volume 14, Issue 17 pp 6917—6935
Identification of immune subtypes to guide immunotherapy and targeted therapy in clear cell renal cell carcinoma
Figure 2. Identification of mutations, immune, and clinicopathological differences among three distinct ccRCC immune-related molecular subtypes. (A) Distribution ratio for grades, stages, T stages, N stages, and M stages across IS1–IS3 in the TCGA cohort. (B) Distribution landscape of mutation and CNV among IS1–IS3 in the TCGA cohort. (C) Distribution landscape of tumor mutation burden among IS1–IS3 in the TCGA cohort. (D) Distribution landscape of mRNAsi status among IS1–IS3 in the TCGA cohort. (E) Distribution landscape of MSI status among IS1–IS3 in the TCGA cohort.